Rare Tumors (Oct 2024)

The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma

  • Foteini Kalofonou,
  • Andrea Napolitano,
  • Charlotte Benson,
  • Aisha Miah,
  • Shane Zaidi,
  • Daniel Lindsay,
  • Khin Thway,
  • Robin L. Jones

DOI
https://doi.org/10.1177/20363613241290788
Journal volume & issue
Vol. 16

Abstract

Read online

We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.